Is Current Evidence Sufficient to Establish the Efficacy of Botulinum Toxin A in Treating Persistent Dry Eye Disease? A Systematic Review and Meta‐Analysis of Interventional Studies With a Critical Review Using GRADE Tool
Open Access
- 16 April 2026
- journal article
- review article
- Published by Wiley in Health Science Reports
- Vol. 9 (4)
Abstract
Background and Aims: Standard management of dry eye disease (DED) relies on artificial tears, anti‐inflammatory therapy, and punctal occlusion in selected cases. However, some patients continue to report persistent symptoms. The present article reviewed the efficacy of Botulinum Toxin A (BTX‐A) for DED that remained symptomatic after these interventions, excluding patients with blepharospasm or hemifacial spasm. Methods: We conducted a comprehensive search of seven databases (PubMed, Embase, Web of Science, Scopus, CENTRAL, Science Direct, and ProQuest), supplemented by grey literature searches (ProQuest, Scopus, OATD), hand‐searching key ophthalmology journals, and investigating clinical trial registries (ClinicalTrials. gov, ICTRP, ISRCTN). Inclusion criteria were clinical trials and cohort studies assessing BTX‐A in primary DED. Outcomes included tear break‐up time (TBUT), Schirmer's test, and Ocular Surface Disease Index (OSDI). Meta‐analyses utilized STATA 17, combining standardized mean differences (SMD) for TBUT and Schirmer's test, and mean difference (MD) for OSDI. Evidence certainty was evaluated using GRADE. Results: Out of 5,064 records, five studies (144 eyes) were included. Meta‐analysis indicated no significant improvements in TBUT (Hedges's g = 0.43, 95% CI: −1.34 to 2.20) or Schirmer's test (Hedges's g = 0.23, 95% CI: −0.78 to 1.24). However, OSDI scores showed a significant reduction (MD –14.23; 95% CI: −15.86 to −12.59, p < 0.001), with moderate‐certainty evidence. Conclusions: BTX‐A injections appear to offer symptom relief in persistent DED, though effects on objective measures remain inconclusive, limited by heterogeneity and low power. While initial safety data is favorable, the small number of methodologically weak studies highlights the need for larger, high‐quality trials to clarify BTX‐A's clinical role. PROSPERO Registration: CRD420251031877.Keywords
This publication has 36 references indexed in Scilit:
- Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile rangeBMC Medical Research Methodology, 2014
- Botulinum neurotoxin type A versus punctal plug insertion in the management of dry eye diseaseOman Journal of Ophthalmology, 2014
- The Cochrane Collaboration's tool for assessing risk of bias in randomised trialsBMJ, 2011
- Treatment of Superior Limbic Keratoconjunctivitis With a Large-Diameter Contact Lens and Botulium Toxin A Treatment of superior limbic keratoconjunctivitis with a large-diameter contact lens and botulium toxin a.Cornea, 2009
- GRADE: an emerging consensus on rating quality of evidence and strength of recommendationsBMJ, 2008
- The Repeatability of Clinical Measurements of Dry EyeCornea, 2004
- Botulinum toxin A treatment in patients suffering from blepharospasm and dry eyeBritish Journal of Ophthalmology, 2003
- Dry eye, blinking, and blepharospasmMovement Disorders, 2002
- Effect of eyelid botulinum toxin injection on lacrimal drainageAmerican Journal of Ophthalmology, 2000
- Treatment of dry eye by blocking the lacrimalcanaliculiSurvey of Ophthalmology, 1996